Please assess the completion status of the following clinical trial:

Trial Title: Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Pre-ASCT Inclusion Criteria~* At least 18 years of age~* Histologically confirmed diagnosis of CD19 positive diffuse large B-cell lymphoma (DLBCL) or transformed large cell lymphoma from low grade lymphoma.~* Chemo-sensitive (defined by complete remission (CR) or partial remission (PR) to most recent chemo regimen) based on pre-transplant positron emission tomography (PET) within 2 months of autologous transplant~* Patients with bulky disease are eligible for study provided that the patient not undergo radiation therapy until 30 days after the end of blinatumomab administration.~* Available representative tissue (from fresh or formalin fixed paraffin embedded tissue) from the most recent biopsy or archival tumor tissue for Clonotype evaluation for minimal residual disease (MRD) testing.~Pre-ASCT Exclusion Criteria~* Chemo-resistant (defined by stable disease (SD) or progressive disease (PD) to most recent chemo regimen)~* Pregnant or breastfeeding~* Active central nervous system (CNS) involvement of Non-Hodgkin's Lymphoma (NHL)~* Clinically relevant CNS pathology such as epilepsy, childhood or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis~* Prior stem cell transplant~* Concurrent hematologic or non-hematologic malignancy requiring treatment~* HIV seropositive, or active Hepatitis A, B, or C infection.~* Uncontrolled congestive heart failure (CHF) or other comorbid systemic illnesses or severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.~Eligibility Criteria to Begin Consolidation Therapy~* A participant must meet all of the following criteria on Day +42 visit in order to continue on the study to begin consolidation therapy with blinatumomab.~* Performance status of Eastern Cooperative Oncology Group (ECOG) ≤ 2 or Karnofsky ≥ 60 %~* Absence of clinically relevant CNS pathology such as epilepsy, paresis, aphasia, stroke, sever brain injuries, dementia, or psychosis~* Required clinical laboratory values:~  * Absolute neutrophil count (ANC) ≥ 1,000~ * Platelets ≥ 75,000~ * Hemoglobin ≥ 8 g/dL~ * Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (unless related to Gilbert's or Meulengracht's syndrome)~ * Alkaline phosphatase ≤ 5 x ULN~ * ALT and AST ≤ 5 x ULN~ * Calculated or measured creatinine clearance ≥ 50ml/min

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ASCT + BEAM + Blinatumomab (Type: EXPERIMENTAL): * Standard of care ASCT with BEAM conditioning (carmustine/etoposide/cytarabine/melphalan) - guidelines below, other conditionings are allowed:~  * carmustine is typically given intravenously (IV) at a dose of 300 mg/m\^2 on Day -7~ * etoposide is typically given IV at a dose of 100 mg/m\^2 twice per day (BID) on Days -6, -5, -4, and -3 (8 doses)~ * cytarabine is typically given IV at a dose of 100 mg/m\^2 BID on Days -6, -5, -4, and -3 (8 doses)~ * melphalan is typically given IV at a dose of 140 mg/m\*2 on Day -2~* Auto-SCT will take place on Day 0 as per institutional guidelines~* Consolidation with blinatumomab will start 6 weeks following auto-SCT. Patients with CR or PR based on pre-transplant PET/CT will receive blinatumomab as a continuous IV infusion (CIVI) at 9μg/day for 1 week, then 28μg/day for 3 weeks (total of 4 weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).